VANCOUVER, British Columbia & SCOTTSDALE, Ariz. & HEIDELBERG, Germany--(BUSINESS WIRE)--April 10, 2006--InNexus Biotechnology, Inc. (TSX.V: IXS)(OTCBB: IXSBF - News) and Affimed Therapeutics today announced a collaboration utilizing Affimed’s antibodies and InNexus’ SuperAntibody antibody enhancement drug development platform. Under terms of the agreement, the companies will complete feasibility studies and InNexus will have a right to license one of Affimed’s antibodies while Affimed will have the right to license SuperAntibody Technology for one antibody. Exercise of rights are expected to trigger payments in the form of licensing fees, milestone payments and sales royalty.
